BioPharm Insight Releases CRO Report on Clinical Trial Activity in 3rd Quarter

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. ISRG
6. TSLA
7. SMCI
8. S
9. COF
10. GOOGL

Go back to BioPharm Insight Releases CRO Report on Clinical Trial Activity in 3rd Quarter

Jefferies Cuts Price Target on Parexel (PRXL) to $67 Following Weak 1Q

October 27, 2016 9:33 AM EDT

Jefferies maintained a Hold rating on PAREXEL International (NASDAQ: PRXL), and cut the price target to $67.00 (from $72.50), following the company's 1Q earnings report. EPS fell 10c below consensus and guidance midpoint. PRXL's revenue shortfall accounted for ~4c. Updated guidance reduces revenue by... More